Search
Charles River Laboratories International Inc
CRLAdd to Watchlist
185.000USD
+2.690+1.48%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
8.91BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Charles River Laboratories International Inc is 7.80, ranking 273 out of 389 in the Biotechnology & Medical Research industry. The average price target is 197.00, with a high of 211.00 and a low of 157.42.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
216.820
Target Price
+18.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Charles River Laboratories International Inc
CRL
20
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Charles River Laboratories International Inc's expected revenue for the next quarter?
Charles River Laboratories International Inc's expected revenue is 973.70M.
What is Charles River Laboratories International Inc's price target?
Analysts forecast that Charles River Laboratories International Inc's price target is USD 197.00, with the highest forecast at USD 211.00 and the lowest forecast at USD 157.42.
How have Charles River Laboratories International IncCRL's recent earnings per share performed?
The market expectation was USD -0.30, while Charles River Laboratories International IncCRL's earnings per share (EPS) for the previous quarter was USD -5.62. EPS for the next quarter is expected at USD 2.73.
What is the analyst rating for Charles River Laboratories International Inc?
Based on the ratings of Charles River Laboratories International Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
